37 Proteomics, Genomics & Microarrays Revolutionary Hydrogel Redefi nes 3D Cell Culture
AMSBIO unveils MatriMix, an revolutionary 3D culture substrate that redefines the field. This cutting-edge hydrogel incorporates fully defined components such as medical grade collagens, laminin-511 E8 fragments, and hyaluronic acid, setting a new standard. With outstanding lot-to-lot consistency, MatriMix empowers researchers to achieve remarkable reproducibility in their experiments.
MatriMix surpasses existing 3D substrates, unlocking new possibilities for advanced applications such as organoid formation with adult patient- derived cells and iPSC culture. Additionally, MatriMix demonstrates remarkable performance in in vivo animal PDX models, further solidifying its exceptional capabilities.
MatriMix, designed as a versatile three-tube formulation kit, provides unrivalled flexibility. Researchers have the freedom to fine-tune the types and concentrations of individual components, tailoring the extracellular environment to perfectly suit their target cells. This exceptional capability unlocks new avenues for cultivating diverse tissue types, expanding the possibilities of cell culture.
With its remarkable capacity to promote exceptional cell organisation and accurately replicate in vivo conditions, MatriMix emerges as the ultimate solution for cultivating challenging cell types and conducting drug screening. Moreover, MatriMix incorporates medical grade porcine collagens, simplifying the transition from fundamental research to clinical applications unlike any other natural hydrogel available.
Extensive validation studies have unequivocally established the versatility of this hydrogel across a diverse range of cell types. These studies have consistently demonstrated its ability to induce organoids with remarkable reproducibility, spanning multiple organ types such as kidney, liver, intestine, and more.
In addition, MatriMix presents practical benefits over other 3D substrates. It is conveniently supplied as a liquid at 4°C, eliminating the requirement for expensive dry ice shipping. When incubated at physiological temperature (37°C), MatriMix transitions into a clear gel, providing enhanced visualisation opportunities for researchers. This unique characteristic adds to the user-friendly nature of MatriMix, simplifying experimental procedures and interpretation.
More information online:
ilmt.co/PL/Zen3 60505pr@reply-direct.com
Advancing Precision Oncology: New NGS Assay for Comprehensive Genomic Profi ling
Agilent Technologies Inc has unveiled the Agilent SureSelect Cancer CGP Assay, a next-generation sequencing (NGS) panel designed for somatic variant profiling in a wide range of solid tumour types. This pan-cancer assay incorporates 679 genes curated from leading cancer databases in collaboration with clinical cancer researchers, expanding the number of biomarkers available for comprehensive genomic profiling. The assay features an efficient, automatable, and flexible workflow, making it accessible to the broader clinical research community.
The biomarkers included in the assay cover various classes of somatic variants, such as SNVs, CNVs, indels, translocations, and de novo gene fusions, as well as immuno-oncology biomarkers like TMB (tumour mutational burden) and MSI (microsatellite instability). These biomarkers provide valuable insights for clinical and translational researchers investigating potential cancer therapeutics. Leveraging Agilent’s industry-leading library prep and target enrichment chemistry, this high-performance assay supports input as low as 10 ng and incorporates walkaway automation to enhance lab efficiency and productivity.
The workflow of the SureSelect Cancer CGP Assay offers flexible data analysis options, including Alissa Interpret for tertiary analysis and reporting, customer bioinformatics pipelines, and third-party software. This comprehensive NGS assay from Agilent empowers precision oncology research by providing up-to-date and globally curated biomarker content for robust molecular profiling of solid tumours.
Dr Alistair Ritchie, Sequencing Laboratory Manager at Glasgow Precision Oncology Laboratory (GPOL), shared his experience with the assay. “The comprehensive coverage of the CGP assay means we can batch DNA from any solid tumour on a single run to streamline our workflow,” he said. “Our team has come to rely on the Agilent SureSelect XT HS2 method for all our target enrichment assays. We have never used a method that gives us such reproducible results with such a low input amount.”
More information online:
ilmt.co/PL/b122 60198pr@reply-direct.com
New Enzyme and Biochemical Catalogue for Life Science Applications
Worthington Biochemical (WBC) has recently unveiled the latest edition of its comprehensive Enzyme and Biochemical Catalogue, now available in both print and digital formats. With the release of the 23rd Edition, WBC presents an extensive range of products tailored for diverse life science applications, encompassing areas such as immunology, cell biology, molecular biology, research, biochemistry, and bioprocessing. This updated catalogue serves as a valuable resource for scientists and researchers seeking top-quality solutions in their respective fields.
Catering to customer demands, the latest catalogue showcases the inclusion of Worthington Animal Free (AF) enzymes. These enzymes, manufactured under ISO9001 Certified and GMP guidelines, are specifically designed for pre-clinical, bioprocessing, and biopharma applications. With an expanded range of Animal Free products, safety is prioritised by reducing the risks associated with BSE/TSE and mammalian virus contaminants.
More information online:
ilmt.co/PL/WM1Z 60382pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
